<DOC>
	<DOCNO>NCT00653458</DOCNO>
	<brief_summary>To compare single-dose bioavailability Ondansetron ODT 8 mg Zofran 8 mg</brief_summary>
	<brief_title>Bioavailability Study Ondansetron Orally Disintegrating Tablets Under Fed Conditions</brief_title>
	<detailed_description>To compare single-dose bioavailability Kali 's Ondansetron ODt 8 mg GlaxoSmithKine 's Zofran 8 mg feed condition</detailed_description>
	<mesh_term>Malnutrition</mesh_term>
	<mesh_term>Ondansetron</mesh_term>
	<criteria>Subjects meet follow criterion may include study Availability subject entire study period willingness adhere protocol requirement evidence informed consent duly sign subject . Males female age 18 50 year body mass index ( BMI ) within 1930 ; demographic data ( sex , age , ethnic group , body weight , height smoke habit ) record report final report . Clinical laboratory value within laboratory 's state normal range ; within range , must without ant clinical significance must record CRF ( laboratory test present section 7.1.3 ) Healthy accord laboratory result physical examination . Normal cardiovascular function accord ECG . Non exsmokers . Significant history hypersensitivity ondansetron related product well severe hypersensitivity reaction ( like angioedema ) drug . Presence history significant gastrointestinal , liver kidney disease , condition know interfere absorption , distribution , metabolism excretion drug know potentiate predispose undesired effect . Presence history significant cardiovascular , pulmonary , hematologic , neurologic , psychiatric , endocrine , immunologic dermatologic disease . Females pregnant , lactate likely become pregnant study phase . Females childbearing potential refuse use acceptable contraceptive regimen throughout study . Positive pregnancy test study . Maintenance therapy drug , significant history drug dependency , alcohol abuse ( &gt; 3 unit alcohol per day , intake excessive alcohol , acute chronic ) , serious psychological disease . Any clinically significant illness previous 28 day day 1 study . Use enzymemodifying drug previous 28 day day 1 study ( barbiturate , corticosteroid , phenylhydantoins , etc . ) Participation another clinical trial previous 28 day day 1 study . Donation 500 mL blood ( Canadian Blood Services , HemaQuebec , clinical study , etc . ) previous 56 day day 1 study . Positive urine screening drug abuse ( drug names present section 7.1.4 ) . Positive result HIV , HBsAg antiHCV test . History faint upon blood sampling .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>bioequivalence</keyword>
	<keyword>Ondansetron ODT</keyword>
	<keyword>fed</keyword>
	<keyword>To determine bioequivalence feed condition</keyword>
</DOC>